Alvydas J Ozinskas

US Patent:

7052831, May 30, 2006

Filed:

Dec 8, 2000

Appl. No.:

09/732838

Inventors:

Robert C. Fletcher - Phoenixville PA, US
Alvydas J. Ozinskas - Dayton MD, US
Kenneth Kopher - Baltimore MD, US
John Gill - Phoenix MD, US

Assignee:

Becton Dickinson and Company - Franklin Lakes NJ

International Classification:

C12Q 1/70

US Classification:

435 5, 422 56, 422 57, 422 58, 422 61, 435 79, 435 792, 4352871, 4352872, 435973, 435975, 436518, 436809

Abstract:

The present invention provides a method and device for conducting a rapid in vitro enzyme immunoassay test for the direct and qualitative detection of two or more viral antigens from specimens of symptomatic patients. The method for immunoassay of viral antigens is performed on a membrane. Non-immunological capture of viral antigens takes place by absorption onto the membrane. Captured antigen binds to a detection reagent that includes a label conjugated to a specific antibody. The test is a differentiated test such that two or more viral antigens may be distinguished from each other in a single test. The invention also includes a kit for performing an assay in accordance with the method of the present invention, wherein the kit comprises the device of the present invention.

US Patent:

56353626, Jun 3, 1997

Filed:

May 23, 1994

Appl. No.:

8/247336

Inventors:

Robert A. Levine - Guilford CT
Stephen C. Wardlaw - Old Saybrook CT
Rodolfo R. Rodriguez - Owings Mills MD
Adrien P. Malick - Granite MD
Alvydas J. Ozinskas - Dayton MD

Assignee:

Becton Dickinson and Co. - Franklin Lakes NJ

International Classification:

G01N 33543
G01N 33558

US Classification:

435 724

Abstract:

A patient's health may be diagnosed by centrifuging blood samples in a transparent tube, which tube contains one or more bodies or groups of bodies such as floats, inserts, liposomes, or plastic beads of different densities. Each density-defined body carries analyte-capture binding materials such as antigens or antibodies, which are specific to an epitope, or other specific high affinity binding site on a target analyte which target analyte may be in the blood or other sample being tested; and the level of which analyte is indicative of the patient's health. At least one labeled binding material which is also specific to an epitope, or other specific high affinity binding site on the target analyte is added to the sample so as to form labeled binding material/analyte/body complexes in the sample. Upon centrifugation, the complexes will settle out in different areas in the tube according to the respective density of the body or bodies; and the degree of label emission of the complex layers can enable qualitative and/or quantitative analyses of the sample to be made. Unbound labeled binding materials will be separated from the complexed layers by the washing action of ascending or descending components of the sample during the centrifugation step.

US Patent:

58342176, Nov 10, 1998

Filed:

Dec 11, 1996

Appl. No.:

8/763858

Inventors:

Robert A. Levine - Guilford CT
Stephen C. Wardlaw - Old Saybrook CT
Leon W. M. M. Terstappen - Palo Alto CA
Kristen L. Manion - Benecia CA
Rodolfo R. Rodriguez - Owings Mills MD
Adrien P. Malick - Granite MD
Subhash Dhanesar - Owings Mills MD
Stephen J. Lovell - Baltimore MD
Alvydas J. Ozinskas - Dayton MD

Assignee:

Becton Dickinson and Co. - Franklin Lakes NJ

International Classification:

G01N 33543
G01N 33546

US Classification:

435 724

Abstract:

A patient's health may be diagnosed by centrifuging blood samples in a transparent tube, which tube contains one or more bodies or groups of bodies such as floats, inserts, liposomes, or plastic beads of different densities. Each density-defined body carries analyte-capture binding materials such as antigens or antibodies, which are specific to an epitope, or other specific high affinity binding site on a target analyte which target analyte may be in the blood or other sample being tested; and the level of which analyte is indicative of the patient's health. At least one labeled binding material which is also specific to an epitope, or other specific high affinity binding site on the target analyte is added to the sample so as to form labeled binding material/analyte/body complexes in the sample. Upon centrifugation, the complexes will settle out in different areas in the tube according to the respective density of the body or bodies; and the degree of label emission of the complex layers can enable qualitative and/or quantitative analyses of the sample to be made. Unbound labeled binding materials will be separated from the complexed layers by the washing action of ascending or descending components of the sample during the centrifugation step.

US Patent:

57767106, Jul 7, 1998

Filed:

Dec 23, 1996

Appl. No.:

8/771507

Inventors:

Robert A. Levine - Guilford CT
Stephen C. Wardlaw - Old Saybrook CT
Leon W. M. M. Terstappen - Palo Alto CA
Kristen L. Manion - Benecia CA
Rodolfo R. Rodriguez - Owings Mills MD
Adrien P. Malick - Granite MD
Subhash Dhanesar - Owings Mills MD
Stephen J. Lovell - Baltimore MD
Alvydas J. Ozinskas - Dayton MD

Assignee:

Becton Dickinson and Co. - Franklin Lakes NJ

International Classification:

G01N 33543
G01N 33558

US Classification:

435 724

Abstract:

A patient's health may be diagnosed by centrifuging blood samples in a transparent tube, which tube contains one or more bodies or groups of bodies such as floats, inserts, liposomes, or plastic beads of different densities. Each density-defined body carries analyte-capture binding materials such as antigens or antibodies, which are specific to an epitope, or other specific high affinity binding site on a target analyte which target analyte may be in the blood or other sample being tested; and the level of which analyte is indicative of the patient's health. At least one labeled binding material which is also specific to an epitope, or other specific high affinity binding site on the target analyte is added to the sample so as to form labeled binding material/analyte/body complexes in the sample. Upon centrifugation, the complexes will settle out in different areas in the tube according to the respective density of the body or bodies; and the degree of label emission of the complex layers can enable qualitative and/or quantitative analyses of the sample to be made. Unbound labeled binding materials will be separated from the complexed layers by the washing action of ascending or descending components of the sample during the centrifugation step.

US Patent:

56311699, May 20, 1997

Filed:

Jan 19, 1994

Appl. No.:

8/183238

Inventors:

Joseph R. Lakowicz - Columbia MD
Badri P. Maliwal - Baltimore MD
Richard Thompson - Baltimore MD
Alvydas Ozinskas - Dayton MD

International Classification:

G01N 33533

US Classification:

436537

Abstract:

A fluorometric luminescence immunoassay method includes forming a sample by exposing a first immune reaction reactant to a second immune reaction reactant capable of reacting with the first reactant, one of the first and second immune reaction reactants being labelled with a photoluminescent energy transfer donor and the other being labelled with a photoluminescent energy transfer acceptor complementary to the photoluminescent donor. At least the photoluminescent donor has the property of photoluminescence, and the photoluminescent donor and acceptor are chosen so that when the first immune reaction reactant reacts with the second immune reaction reactant, the donor and the acceptor are capable of interacting to produce a detectable luminescence lifetime change. The sample is excited with radiation, and the resulting emission is detected. The apparent luminescent lifetime is then calculated to determine the presence of a reaction product of the first and second immune reaction reactants.